PDS BIOTECHNOLOGY CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.93 USD | -2.66% |
|
+10.98% | -41.05% |
| 06-24 | Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer | CI |
| 06-12 | B. Riley Lowers Price Target on PDS Biotechnology to $9 From $11, Maintains Buy Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Bio Therapeutic Drugs | -2.66% | +10.98% | -41.05% | -46.34% | -51.09% | 107M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- PDSB Stock
- Charts PDS Biotechnology Corporation
- Comparison Chart
